- Home
- PETS vs DTIL Comparison
PETS vs DTIL Comparison
Compare PETS & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | DTIL |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 128.8M |
| IPO Year | 2003 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PETS | DTIL |
|---|---|---|
| Price | $2.37 | $5.62 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.20 | ★ $60.00 |
| AVG Volume (30 Days) | 105.8K | ★ 180.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $273,800,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | $34.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $3.53 |
| 52 Week High | $4.32 | $8.82 |
Technical Indicators
Market Signals| Indicator | PETS | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 25.37 | 73.04 |
| Support Level | N/A | $4.50 |
| Resistance Level | $2.93 | $5.80 |
| Average True Range (ATR) | 0.11 | 0.36 |
| MACD | -0.03 | 0.16 |
| Stochastic Oscillator | 14.04 | 79.86 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.